- Home
- CERO vs RDHL Comparison
CERO vs RDHL Comparison
Compare CERO & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- RDHL
- Stock Information
- Founded
- CERO 2017
- RDHL 2009
- Country
- CERO United States
- RDHL Israel
- Employees
- CERO N/A
- RDHL N/A
- Industry
- CERO
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- RDHL Health Care
- Exchange
- CERO Nasdaq
- RDHL Nasdaq
- Market Cap
- CERO 6.1M
- RDHL 3.9M
- IPO Year
- CERO N/A
- RDHL N/A
- Fundamental
- Price
- CERO $1.99
- RDHL $1.50
- Analyst Decision
- CERO Strong Buy
- RDHL
- Analyst Count
- CERO 2
- RDHL 0
- Target Price
- CERO $45.00
- RDHL N/A
- AVG Volume (30 Days)
- CERO 291.2K
- RDHL 2.9M
- Earning Date
- CERO 11-18-2025
- RDHL 09-05-2025
- Dividend Yield
- CERO N/A
- RDHL N/A
- EPS Growth
- CERO N/A
- RDHL N/A
- EPS
- CERO N/A
- RDHL N/A
- Revenue
- CERO N/A
- RDHL $9,550,000.00
- Revenue This Year
- CERO N/A
- RDHL $381.91
- Revenue Next Year
- CERO N/A
- RDHL N/A
- P/E Ratio
- CERO N/A
- RDHL N/A
- Revenue Growth
- CERO N/A
- RDHL 157.62
- 52 Week Low
- CERO $1.93
- RDHL $1.06
- 52 Week High
- CERO $895.40
- RDHL $9.00
- Technical
- Relative Strength Index (RSI)
- CERO 14.42
- RDHL 41.10
- Support Level
- CERO $5.18
- RDHL $1.55
- Resistance Level
- CERO $5.66
- RDHL $1.97
- Average True Range (ATR)
- CERO 0.42
- RDHL 0.21
- MACD
- CERO -0.26
- RDHL -0.07
- Stochastic Oscillator
- CERO 1.61
- RDHL 0.00
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.